<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery

Biodesix highlighted their development and commercialization of companion diagnostics for directing the treatment of non-small cell lung cancer at the 2019 Clinical Biomarkers & World CDx Conference.

Biodesix Announces New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy

Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.

Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team

Biodesix appointed Robert W. Georgantas III, Ph.D., as the company’s Senior Vice President (SVP) of Research and Translational Science.

Biodesix Adds Dr. Charles Watts to Board of Directors

Biodesix announces the appointment of Charles Watts, M.D. to the company’s board of directors.

Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers

Biodesix announced that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.

Biodesix Reaches Agreement to Deliver Next-Generation Sequencing Assay for Blood-Based Companion Diagnostic Solutions in Cancer

Biodesix has entered into an agreement with Thermo Fisher Scientific.

Biodesix to Acquire Oncimmune in the United States

Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.

Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR

Biodesix will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy

Biodesix VeriStrat Data Demonstrate Independent Prediction of Immunotherapy Outcomes for NSCLC Patients

Biodesix presented new data showing that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer treated with immune checkpoint inhibitors

MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics

MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.

First 1 2 3 4 5 6 7 8 9 Last